Loading
Life sciences · Journal article
Al-rafidain Journal of Medical Sciences · October 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecologic malignancy, and predicting its outcomes is complicated by two interlinked adversaries: the near-inevitable development of platinum resistance that depletes the most successful drug class against the disease and a profound molecular and antigenic heterogeneity that defies targeted therapy. Antibody-drug conjugates (ADCs) directed against tumor-associated antigens offer a strategically attractive answer to both because they kill through a cytotoxic mechanism of microtubule disruption by a delivered payload that is wholly independent of the DNA-repair and drug-handling pathways that confer platinum resistance and because the bystander effect of their membrane-permeable payloads can reach antigen-negative cells within a heterogeneous tumor. This review examines two complementary antigens that researchers are pursuing in HGSOC. Folate receptor alpha (FRα), overexpressed in the great majority of these tumors, is the target of mirvetuximab soravtansine, the first agent of any class to demonstrate an overall-survival benefit in platinum-resistant ovarian cancer and the first ADC approved for this disease. Claudin-6 (CLDN6), an oncofetal tight-junction protein essentially absent from normal adult tissue and expressed in roughly half of HGSOC, is the target of the first-in-class ADC TORL-1-23, which has shown encouraging response rates in platinum-resistant disease in early-phase testing. We detail the biology and resistance mechanisms of HGSOC; the rationale by which antigen-directed payload delivery bypasses platinum resistance; the design, clinical validation, and pipeline of FRα- and CLDN6-targeted ADCs; the way bystander killing, complementary antigen coverage, and biomarker-guided selection address heterogeneity; the safety; and resistance.